New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission Pharmaceutical Investing
BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study Life Science Investing
AbbVie Announces First Provincial Reimbursement for VENCLEXTA® with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia in Quebec Pharmaceutical Investing
Gilead Exercises Options to Three Arcus Biosciences Clinical-stage Programs and Adds Research Collaboration Pharmaceutical Investing
Bristol Myers Squibb Awards "Golden Tickets" to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs Pharmaceutical Investing
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HMLP, NVAX Investors, Lead Plaintiff Deadlines Set Pharmaceutical Investing
Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation Challenge Market News
AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® for the Treatment of Adults with Active Psoriatic Arthritis Pharmaceutical Investing
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, HEPS, HMLP and HYZN Pharmaceutical Investing
SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, EAR, HEPS, HMLP INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits Pharmaceutical Investing
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses Pharmaceutical Investing
